 Anemia, Sickle Cell
"Anemia, Sickle Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Descriptor ID |
D000755
|
| MeSH Number(s) |
C15.378.071.141.150.150 C15.378.420.155 C16.320.070.150 C16.320.365.155
|
| Concept/Terms |
Anemia, Sickle Cell- Anemia, Sickle Cell
- Anemias, Sickle Cell
- Sickle Cell Anemias
- Sickling Disorder Due to Hemoglobin S
- Sickle Cell Disease
- Cell Disease, Sickle
- Cell Diseases, Sickle
- Sickle Cell Diseases
- Sickle Cell Disorders
- Cell Disorder, Sickle
- Cell Disorders, Sickle
- Sickle Cell Disorder
- Hemoglobin S Disease
- Disease, Hemoglobin S
- Hemoglobin S Diseases
- Sickle Cell Anemia
|
Below are MeSH descriptors whose meaning is more general than "Anemia, Sickle Cell".
- Diseases [C]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Anemia [C15.378.071]
- Anemia, Hemolytic [C15.378.071.141]
- Anemia, Hemolytic, Congenital [C15.378.071.141.150]
- Anemia, Sickle Cell [C15.378.071.141.150.150]
- Hemoglobinopathies [C15.378.420]
- Anemia, Sickle Cell [C15.378.420.155]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Anemia, Hemolytic, Congenital [C16.320.070]
- Anemia, Sickle Cell [C16.320.070.150]
- Hemoglobinopathies [C16.320.365]
- Anemia, Sickle Cell [C16.320.365.155]
Below are MeSH descriptors whose meaning is more specific than "Anemia, Sickle Cell".
This graph shows the total number of publications written about "Anemia, Sickle Cell" by people in this website by year, and whether "Anemia, Sickle Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1984 | 1 | 0 | 1 | | 1986 | 1 | 0 | 1 | | 1987 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 3 | 1 | 4 | | 1991 | 1 | 0 | 1 | | 1993 | 1 | 1 | 2 | | 1994 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 1 | 2 | 3 | | 2003 | 0 | 1 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 4 | 0 | 4 | | 2010 | 6 | 1 | 7 | | 2011 | 2 | 1 | 3 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 3 | 1 | 4 | | 2015 | 4 | 1 | 5 | | 2016 | 6 | 0 | 6 | | 2017 | 4 | 1 | 5 | | 2018 | 8 | 0 | 8 | | 2019 | 2 | 0 | 2 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Anemia, Sickle Cell" by people in Profiles.
-
Payne AB, Mehal JM, Chapman C, Haberling DL, Richardson LC, Bean CJ, Hooper WC. Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020 09; 76(3S):S28-S36.
-
Kayle M, Valle J, Paulukonis S, Holl JL, Tanabe P, French DD, Garg R, Liem RI, Badawy SM, Treadwell MJ. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease. Pediatr Blood Cancer. 2020 05; 67(5):e28152.
-
Ross LF. 50 Years Ago in TheJournal ofPediatrics: A New Diagnostic Test for Hemoglobin S. J Pediatr. 2020 01; 216:18.
-
Viner M, Zhou J, Allison D, Han J, Molokie RE, Jain S, Gowhari M, Gordeuk VR, Calip G, Saraf SL. The morbidity and mortality of end stage renal disease in sickle cell disease. Am J Hematol. 2019 05; 94(5):E138-E141.
-
Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):297-308.
-
Saraf SL, Viner M, Rischall A, Raslan R, Shah BN, Zhang X, Han J, Gowhari M, Jain S, Molokie RE, Machado RF, Lash JP, Gordeuk VR. HMOX1 and acute kidney injury in sickle cell anemia. Blood. 2018 10 11; 132(15):1621-1625.
-
Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Exp Hematol. 2018 11; 67:60-64.e2.
-
Rivers A, Jagadeeswaran R, Lavelle D. Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data. . 2018 10 01; 315(4):R840-R847.
-
Biller E, Zhao Y, Berg M, Boggio L, Capocelli KE, Fang DC, Koepsell S, Music-Aplenc L, Pham HP, Treml A, Weiss J, Wool G, Baron BW. Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB. Transfusion. 2018 08; 58(8):1965-1972.
-
Amlie-Lefond C, Flanagan J, Kanter J, Dobyns WB. The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia. J Stroke Cerebrovasc Dis. 2018 Nov; 27(11):2897-2904.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|